Adenocarcinoma of the Prostate

1. Front Matter

   Pages i-xiii

   PDF

2. Epidemiology

   • J. M. G. Wilson

   Pages 1-28

3. Grading of Prostatic Carcinomas—Current Status

   • F. K. Mostofi

   Pages 29-46

4. Tumor Markers in Prostatic Disease

   • A. W. Bruce, B. K. Choe

   Pages 47-62

5. Hormone Receptors in Prostatic Cancer

   • B. G. Mobbs, J. G. Connolly

   Pages 63-81

6. Imaging Techniques in the Diagnosis and Pelvic Staging of Prostatic Cancer

   • P. N. Bretan, R. D. Williams

   Pages 83-106

7. Update in Staging Systems

   • P. C. Sogani, W. F. Whitmore Jr.

   Pages 107-115

8. Pelvic Lymph Nodes: Diagnosis and Significance

   • J. I. Harty, W. J. Catalona

   Pages 117-128

9. Management of Localized Adenocarcinoma of the Prostate

   • C. A. Olsson

   Pages 129-144

10. Interstitial Radiotherapy

    • P. T. Scardino, F. Bretas

    Pages 145-158

11. The Case for External Beam Radiotherapy of Certain Adenocarcinomas of the Prostate

    • M. Bagshaw

    Pages 159-172

12. Hormonal Therapy in Metastatic Prostatic Cancer

    • J. Trachtenberg

    Pages 173-184

13. Chemotherapy of Prostatic Cancer

    • R. P. Huben, G. P. Murphy

    Pages 185-196

14. Clinical Trials in Prostatic Cancer: Methodology and Controversies

    • H. I. Scher, A. Yagoda

    Pages 197-219

15. Back Matter

    Pages 221-225

    PDF

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.

• Grading
• Staging
• Tumor
• cancer
• carcinoma
• chemotherapy
• clinical trial
• diagnosis
• epidemiology
• hormones
• imaging
• imaging techniques
• prostate
• radiotherapy
• urology
• Radiaton Oncology

• Division of Urology, University of Toronto, Toronto General Hospital, Toronto, Canada

  Andrew W. Bruce, John Trachtenberg

• Ministry of Health, Canada

  John Trachtenberg

Policies and ethics